Extracorporeal Therapy for Dabigatran Removal in the Treatment of Acute Bleeding
Authors:
Open Access
- 1 September 2013
- journal article
- case report
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 8 (9) , 1533-1539
Abstract
Summary: Background and objectives: Dabigatran is an oral direct thrombin inhibitor that is Food and Drug Administration-approved for prevention of stroke in patients with atrial fibrillation. No antidote is available for reversal of dabigatran’s anticoagulant effect. Despite limited clinical data, hemodialysis has been suggested as a strategy to remove dabigatran during acute bleeding. This work presents five cases, in which extracorporeal therapy was performed for dabigatran removal in acutely bleeding patients. Design, setting, participants, & measurements: The series is comprised of five consecutive cases of patients receiving dabigatran 150 mg per os two times daily who were admitted with life-threatening bleeding between March of 2012 and January of 2013. Dabigatran plasma concentrations ranged from 149 to 1200 ng/ml. Treatment included administration of blood products to all patients and then, high-flux intermittent hemodialysis alone or followed by continuous renal replacement therapy. Results: Dabigatran concentrations decreased by 52%–77% during intermittent hemodialysis but rebounded up to 87% within 2 hours after completion of dialysis. Initiation of continuous renal replacement therapy after intermittent hemodialysis attenuated the rebound effect in one patient and contributed to a reduction in dabigatran concentrations of 81% over 30 hours. Conclusions: Extracorporeal therapy lowered dabigatran concentrations, suggesting that it removed the drug and may effectively accelerate total clearance, especially in patients with impaired kidney function. The use of prolonged intermittent hemodialysis or intermittent hemodialysis followed by continuous renal replacement therapy is recommended for the management of life-threatening bleeding in patients receiving dabigatran. The advantage of extracorporeal therapy should be weighed against the risk of bleeding with catheter insertion.Keywords
This publication has 31 references indexed in Scilit:
- Treatment of Dabigatran-Associated BleedingJournal of Pharmacy Practice, 2012
- Clinical Challenges in a Patient With Dabigatran-Induced Fatal HemorrhageThe American Journal of Geriatric Pharmacotherapy, 2012
- Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial FibrillationCirculation, 2011
- Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran EtexilateClinical Pharmacokinetics, 2010
- Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly SubjectsClinical Pharmacokinetics, 2008
- Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin??Inhibitor Dabigatran EtexilateClinical Pharmacokinetics, 2008
- The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjectsBritish Journal of Clinical Pharmacology, 2007
- Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysisBritish Journal of Clinical Pharmacology, 2006
- The Ecarin Clotting Time, a Universal Method to Quantify Direct Thrombin InhibitorsPathophysiology of Haemostasis and Thrombosis, 2003
- Pharmacokinetic evaluation of hemodialysis in acute drug overdoseJournal of Pharmacokinetics and Biopharmaceutics, 1978